These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37913732)

  • 21. Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse.
    Lin C; Yu B; Liu X; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
    Biomed Pharmacother; 2022 Jun; 150():112984. PubMed ID: 35447541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice.
    Wu H; Liu G; He Y; Da J; Xie B
    Eur J Pharmacol; 2019 Sep; 858():172393. PubMed ID: 31085240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy.
    Zhou L; Liang Q; Li Y; Cao Y; Li J; Yang J; Liu J; Bi J; Liu Y
    Acta Biomater; 2022 Oct; 152():235-254. PubMed ID: 36087869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice.
    Li WC; Zhao SX; Ren WG; Zhang YG; Wang RQ; Kong LB; Zhang QS; Nan YM
    Exp Ther Med; 2021 Aug; 22(2):830. PubMed ID: 34149876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3D hESC exosomes enriched with miR-6766-3p ameliorates liver fibrosis by attenuating activated stellate cells through targeting the TGFβRII-SMADS pathway.
    Wang N; Li X; Zhong Z; Qiu Y; Liu S; Wu H; Tang X; Chen C; Fu Y; Chen Q; Guo T; Li J; Zhang S; Zern MA; Ma K; Wang B; Ou Y; Gu W; Cao J; Chen H; Duan Y
    J Nanobiotechnology; 2021 Dec; 19(1):437. PubMed ID: 34930304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
    Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
    Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exosomes derived from natural killer cells inhibit hepatic stellate cell activation and liver fibrosis.
    Wang L; Wang Y; Quan J
    Hum Cell; 2020 Jul; 33(3):582-589. PubMed ID: 32449114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oligochitosan-based nanovesicles for nonalcoholic fatty liver disease treatment via the FXR/miR-34a/SIRT1 regulatory loop.
    Kong M; Peng Y; Qiu L
    Acta Biomater; 2023 Jul; 164():435-446. PubMed ID: 37040811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction.
    An P; Wei G; Huang P; Li W; Qi X; Lin Y; Vaid KA; Wang J; Zhang S; Li Y; Or YS; Jiang LJ; Popov YV
    Liver Int; 2020 Jul; 40(7):1655-1669. PubMed ID: 32329946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand.
    Carino A; Biagioli M; Marchianò S; Scarpelli P; Zampella A; Limongelli V; Fiorucci S
    Pharmacol Res; 2018 May; 131():17-31. PubMed ID: 29530598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
    J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.
    Vignozzi L; Morelli A; Cellai I; Filippi S; Comeglio P; Sarchielli E; Maneschi E; Vannelli GB; Adorini L; Maggi M
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):277-292. PubMed ID: 27425465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.
    Pereira-Fantini PM; Lapthorne S; Gahan CGM; Joyce SA; Charles J; Fuller PJ; Bines JE
    Cell Mol Gastroenterol Hepatol; 2017 Jul; 4(1):65-74. PubMed ID: 28560290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of Intestinal UDP-Glucuronosyltransferase 1A1 by the Farnesoid X Receptor Agonist Obeticholic Acid Is Controlled by Constitutive Androstane Receptor through Intestinal Maturation.
    Weber AA; Mennillo E; Yang X; van der Schoor LWE; Jonker JW; Chen S; Tukey RH
    Drug Metab Dispos; 2021 Jan; 49(1):12-19. PubMed ID: 33154041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
    Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
    Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effect of Mesenchymal Stem Cell-Derived Exosomes and miR17-5p Inhibitor on Multicellular Liver Fibrosis Microtissues.
    Sani F; Soufi Zomorrod M; Azarpira N; Soleimani M
    Stem Cells Int; 2023; 2023():8836452. PubMed ID: 37576406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.
    Gao J; Wei B; de Assuncao TM; Liu Z; Hu X; Ibrahim S; Cooper SA; Cao S; Shah VH; Kostallari E
    J Hepatol; 2020 Nov; 73(5):1144-1154. PubMed ID: 32389810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction.
    Xu W; Lu C; Zhang F; Shao J; Yao S; Zheng S
    FEBS J; 2017 Jan; 284(1):114-133. PubMed ID: 27896916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.
    Roth JD; Veidal SS; Fensholdt LKD; Rigbolt KTG; Papazyan R; Nielsen JC; Feigh M; Vrang N; Young M; Jelsing J; Adorini L; Hansen HH
    Sci Rep; 2019 Jun; 9(1):9046. PubMed ID: 31227742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.